OBJECTIVE:
To evaluate the impact of both
pretreatment thrombocytosis, and platelet count reduction post-adjuvant
chemotherapy, on survival in patients with advanced epithelial ovarian
cancer.
METHODS:
Records of 179 women who underwent
cytoreductive surgery for FIGO stage III or IV epithelial ovarian cancer
and received six cycles of platinum/paclitaxel-based chemotherapy
between July1998 and March 2009 were retrospectively reviewed.....
RESULTS:
Sixty-two
of 179 (
34.6%) patients had thrombocytosis at
primary diagnosis.
Patients with preoperative thrombocytosis had greater elevations of
CA-125 (p<0.0001) and a
greater volume of ascites (p=0.007). On
multivariate analysis, thrombocytosis and CA-125 elevation retained
significance as indicators of poor prognosis in patients with stage III
or IV disease. In patients with
normal CA-125 after chemotherapy, a high
platelet ratio was an independent risk factor for reduced survival
(p=0.05).
CONCLUSIONS:
Preoperative thrombocytosis and a
high platelet ratio appear to be poor prognostic factors of survival in
patients with advanced epithelial ovarian cancer who were treated with
cytoreductive surgery and adjuvant platinum/paclitaxel-based
chemotherapy
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.